Oral chemotherapy can be a viable alternative to intravenous infusions, though it may have its own challenges, such as unpleasant taste. Taste alterations are common side effects of cancer treatments, ...
CBX-12 targets tumor cells with exatecan, offering potential for patients ineligible for antigen-targeted therapies. Phase 2 trial evaluates CBX-12's safety, tolerability, and efficacy in ...